Keywords: genta, antisense, cancer, phase, ii, started, trial

Genta's antisense for cancer in Phase II

Article | 28 January 1999

Print This

Genta has started a trial in the UK of G3139, its bcl-2 gene-targetingantisense drug for the treatment of non-Hodgkin's lymphoma. ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in